Founded in 1999, InSightec operates in medical devices. Its shares do not trade on a public exchange.
InSightec has no published valuation.
GE HealthcareInSightec is an Israeli medical device company that develops MR-guided Focused Ultrasound technology, marketed under the Exablate brand, to treat conditions such as essential tremor, tremor-dominant Parkinson's disease and uterine fibroids without incisions. Founded in 1999 by Kobi Vortman and Oded Tamir with seed investment from Elbit Medical Imaging and GE Healthcare, the company is headquartered in Tirat Carmel with offices in Dallas, Miami, Tokyo and Shanghai.
By 2019 its technology had been used in more than 50 medical centers worldwide to treat over 2,000 patients, and in December 2025 InSightec spun out Lotus Neuro, a clinical-stage biotech company that pairs focused ultrasound with drug delivery for brain-targeted therapies.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds InSightec.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. InSightec availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — InSightec included.
The routes section explains what is realistically available for a company at this stage.
No. InSightec is a private company; its shares do not trade on a public exchange.
Lead investors for each round are in the funding timeline.
The closest medical devices peers are on the competitors page.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
